Zydus Cadila gets FDA’s approval to market generic cancer drug in US

0
24


Image source: PTI FILE

Decitabine is used to treat myelodysplastic syndromes, some types of cancer of the blood or bone marrow. According to the manufacturer, the drug will be manufactured at the group’s plant for the production of injectables.

Pharmaceutical company Zydus Cadila on Saturday said it had received approval from the U.S. health regulator to sell decitabine injections used to treat certain types of cancer on the U.S. market.

The company has received final approval from the United States Food and Drug Administration (USFDA) for decitabine for injection at 50 mg / single dose vial, Zydus Cadila said in a statement.

Decitabine is used to treat myelodysplastic syndromes, some types of cancer of the blood or bone marrow. According to the manufacturer, the drug will be manufactured at the group’s plant for the production of injectables.

The Zydus Group currently has 326 approvals and has filed over 400 Abbreviated New Drugs Applications (ANDA) since the filing began in 2003-04.

ALSO READ | Center to purchase 1 crore of Zydus Cadila COVID vaccinations at Rs 265 per dose

ALSO READ | The Zydus Cadila Covid vaccine will currently only be administered to adults: Sources

Latest world news



LEAVE A REPLY

Please enter your comment!
Please enter your name here